APX 2014
Alternative Names: APX-2014Latest Information Update: 24 Oct 2024
At a glance
- Originator Apexian Pharmaceuticals
- Class Eye disorder therapies; Small molecules
- Mechanism of Action APEX1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration; Dry age-related macular degeneration